Article
03 Sep 2025
FDA's Removal Of Semaglutide And The Evolving Tirzepatide Decisions: What Compounders Need To Know
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
07 Aug 2025
Major Update On GLP-1 Litigation Involving Compounding Pharmacies
Article
26 Jun 2025
Color Us Intrigued: Staying Ahead Of FDA's Regulatory Changes For Colors
Article
29 May 2025
State Importation Revamped: FDA Announces Enhancements To State Importation For Eligible Prescription Drugs
Article
22 May 2025
Formula For Change: FDA Open The Door For Input On Nutrient Requirements For Infant Formula
Article
19 May 2025
Tirzepatide Ruling: Implications For Compounders In An Evolving Legal Landscape
Article
23 Apr 2025
The High Cost Of Trust: What Pharmacies Must Learn From The Rise Of Counterfeit GLP-1 Product Sales
Article
04 Feb 2025
FDA Reopens Door For Flavored Cigars And Menthol Cigarettes
Article
31 Jan 2025
Tirzepatide, FDA, And Compounding: Understanding The Current Landscape
Article
29 Jan 2025
Navigating The FDA's Final Interim Policy On Compounding With Bulk Drug Substances: A Guide For 503A Pharmacies And 503B Outsourcing Facilities
Article
20 Jan 2025
4 Potential FDA Drug Approvals To Watch In 2025
Article
02 Jan 2025
FDA Removed Tirzepatide From The Drug Shortage List
Article
17 Dec 2024
FDA Issues 115 Warning Letters To Retailers Selling Unauthorized E-Cigarettes
